Cross-institution positioning
May 11, 2026Mixed positioning. No institution has two comparable Schedule 13 observations yet.
Source: Schedule 13 researchSPTX Institutional Ownership
Seaport Therapeutics, Inc.
Latest stored close $18.15 as of Oct 9, 2026 View live quote ↗
STOCKNODE Outlook
Neutral
55/100
1 tracked · 0 comparable
Latest filing
May 11, 2026
Positive breadth
1 positive · 0 negative
Recent close
$18.15
Research confidence
Limited
Institutional Research 55/100 · 0 accumulating · 0 reducing / exited
Ownership history
Reported ownership % history
Latest filing May 11, 2026
See how each tracked institution's reported ownership changed across SEC position dates. Full history is available with Investor or Pro access.
Locked preview
Unlock the reported ownership timeline
Unlock full research
Accumulating0
Newly reported1
Reducing / exited
0
52-week position
—
Institutional Intelligence
Why STOCKNODE says Neutral
What the evidence shows across the newest institutional, insider, company-event, 13F, fundamental, and price data; STOCKNODE combines these layers into a quantitative research signal while preserving each source and reporting window.
STOCKNODE Outlook
Neutral 55/100
Confidence:Limited
Why this signal
- 0 tracked institutions accumulating versus 0 reducing/exited.
- Latest comparable Form 13F activity is net positive across tracked managers.
Conflicting evidence
- Institutions are bullish while comparable SEC fundamentals are deteriorating.
Institutional
61/100
Insiders
59/100
Fundamentals
30/100
Events
50/100
Quarterly 13F activity
Jun 30, 20261 increased/new, 0 reduced/exited across 1 manager in the latest comparable Form 13F quarter.
Source: Form 13F quarter-end holdingsInsider filing activity
Jun 22, 2026Over the last 90 days, SEC-coded non-derivative P/S activity includes 1 purchase by 1 reporting owner and 0 sales by 0 reporting owners. Amendments are shown in the filing evidence but excluded from rolling activity totals.
Source: SEC Forms 3/4/5Material company events
Aug 3, 20261 non-amendment material event in the last 90 days; Latest classified evidence: Results of operations / financial condition. Registration and prospectus filings are treated as financing capacity/disclosure evidence, not proof that securities were sold.
Source: SEC 8-K / securities filing metadataSEC fundamentals
Aug 3, 2026Net income -315.2% YoY; Free cash flow -29.2% YoY. Periods are compared only when the SEC facts are aligned and comparable.
Source: SEC Company FactsPrice context
Sep 15, 2026Recent close is 60% through its reported 52-week range.
Source: Stored historical price series
Latest filing decision brief
Investor / Pro
Research the latest Initial Schedule 13G from Goldman Sachs Group.
Filed May 11, 2026. Unlock the dated position comparison, disclosure classification, confidence, price context, and filing-specific significance analysis.
Premium research values are withheld until unlocked.
Supporting institutional evidence
Institutional Evidence
The research summary above gives the current read. This section shows the dated holder-level evidence behind it.
Latest filing
May 11, 2026
Latest reported position changes
Investor / Pro detailSee each institution's newest reported position against its own prior report, with position as-of date separated from SEC filed date. Institution names and filing freshness remain public below.
Goldman Sachs Group
Filed May 11, 2026
Direction locked
Unlock the actual direction, share change, ownership change, and classification basis.
No premium position values are sent in this locked preview.
Unlock full research
Reported direction breadth by as-of date
Locked previewComparable holder direction grouped by SEC position as-of date — never presented as trade dates.
Unlock actual accumulation vs. reduction breadth across reported position dates.
View plans
Institution comparison
Investor / Pro detailCompare each institution only with its own prior reported position. Public visitors can see who is tracked and how fresh the filing is; paid research reveals the actual comparison.
Goldman Sachs Group
Filed May 11, 2026
Unlock the evidence behind the score
Know who changed position, by how much, and when the SEC learned about it.
Investor and Pro reveal holder-by-holder changes, reported ownership history, dated breadth, disclosure timing, institution comparison, and filing-specific analysis without treating Schedule 13 reports as trade dates.
✓ Actual share and ownership changes
✓ Position as-of date vs. SEC filed date
✓ Deterministic direction basis
✓ Full evidence on every eligible stock
SEC Forms 3, 4 & 5
Insider activity
Reported Section 16 ownership activity. Rolling purchase/sale totals use non-derivative SEC transaction codes P and S only; amendments remain visible but are excluded from those totals.
30-day purchases00 reporting owner(s)
30-day sales00 reporting owner(s)
90-day purchase breadth1
90-day sale breadth0
View recent insider filing evidence
| Date | Reporting owner | Code | Security | Shares | Price | Ownership | Filed |
|---|---|---|---|---|---|---|---|
| Jun 22, 2026 | HOMBACH ROBERT J. | POpen-market or private purchase | Common Stock | 13.0K | $18.14 | Indirect | Jun 24, 2026 |
| May 4, 2026 | PureTech Health plc, PureTech LYT, Inc. | CConversion of derivative · derivative | Series B Preferred Stock | 3.0M | $0.00 | Indirect | May 6, 2026 |
| May 4, 2026 | PureTech Health plc, PureTech LYT, Inc. | CConversion of derivative · derivative | Series A-2 Preferred Stock | 8.4M | $0.00 | Indirect | May 6, 2026 |
| May 4, 2026 | PureTech Health plc, PureTech LYT, Inc. | CConversion of derivative · derivative | Series A-1 Preferred Stock | 40.0M | $0.00 | Indirect | May 6, 2026 |
| May 4, 2026 | PureTech Health plc, PureTech LYT, Inc. | CConversion of derivative | Common Stock | 965.3K | — | Indirect | May 6, 2026 |
| May 4, 2026 | PureTech Health plc, PureTech LYT, Inc. | CConversion of derivative | Common Stock | 2.7M | — | Indirect | May 6, 2026 |
| May 4, 2026 | PureTech Health plc, PureTech LYT, Inc. | CConversion of derivative | Common Stock | 12.7M | — | Indirect | May 6, 2026 |
| May 4, 2026 | HEALY JAMES | CConversion of derivative · derivative | Series B Preferred Stock | 2.5M | $0.00 | Indirect | May 4, 2026 |
| May 4, 2026 | HEALY JAMES | CConversion of derivative · derivative | Series A-2 Preferred Stock | 6.1M | $0.00 | Indirect | May 4, 2026 |
| May 4, 2026 | HEALY JAMES | CConversion of derivative | Common Stock | 804.4K | — | Indirect | May 4, 2026 |
| May 4, 2026 | HEALY JAMES | CConversion of derivative | Common Stock | 1.9M | — | Indirect | May 4, 2026 |
| May 4, 2026 | White Lauren | CConversion of derivative · derivative | Series B Preferred Stock | 21.1K | $0.00 | Indirect | May 4, 2026 |
| May 4, 2026 | White Lauren | CConversion of derivative | Common Stock | 6.7K | — | Indirect | May 4, 2026 |
| May 4, 2026 | Gladstein Lana | CConversion of derivative · derivative | Series B Preferred Stock | 105.3K | $0.00 | Direct | May 4, 2026 |
| May 4, 2026 | Gladstein Lana | CConversion of derivative | Common Stock | 33.5K | — | Direct | May 4, 2026 |
| May 4, 2026 | Chen Michael Cunyuan | CConversion of derivative · derivative | Series B Preferred Stock | 10.5K | $0.00 | Direct | May 4, 2026 |
| May 4, 2026 | Chen Michael Cunyuan | CConversion of derivative | Common Stock | 3.4K | — | Direct | May 4, 2026 |
| May 4, 2026 | Torres Denice | CConversion of derivative · derivative | Series B Preferred Stock | 42.1K | $0.00 | Indirect | May 4, 2026 |
| May 4, 2026 | Torres Denice | CConversion of derivative | Common Stock | 13.4K | — | Indirect | May 4, 2026 |
| May 4, 2026 | PAUL STEVEN M | CConversion of derivative · derivative | Series B Preferred Stock | 210.5K | $0.00 | Direct | May 4, 2026 |
SEC company-event context
Material company events
Recent 8-K item classifications plus securities registration and prospectus filings. Registration or prospectus filings show financing capacity/disclosure activity; they do not by themselves prove that securities were sold.
30-day material events0
90-day capital-related0
90-day equity-related0
90-day debt-related0
View recent company-event filing evidence
| Filed | Form | 8-K item(s) | Classification | Capital context | SEC |
|---|---|---|---|---|---|
| Aug 3, 2026 | 8-K | 2.02, 9.01 | Results of operations / financial condition; Financial statements / exhibits | — | Filing |
| Jun 8, 2026 | 8-K | 2.02, 9.01 | Results of operations / financial condition; Financial statements / exhibits | — | Filing |
| May 4, 2026 | 8-K | 5.03, 9.01 | Charter or bylaw change; Financial statements / exhibits | — | Filing |
| May 4, 2026 | S-8 | — | Employee-plan securities registration | Equity | Filing |
| May 1, 2026 | 424B4 | — | Prospectus filing | Capital-related | Filing |
| Apr 27, 2026 | S-1/AAmendment | — | Securities registration statement | Capital-related | Filing |
| Apr 10, 2026 | S-1 | — | Securities registration statement | Capital-related | Filing |
SEC-reported company fundamentals
Fundamentals
Period-aligned SEC facts. Comparisons appear only when periods and units are comparable.
Operating income
$-65.8M
Q2 2026
-256.3% YoY 10-Q filed Aug 3, 2026
Net income
$-62.6M
Q2 2026
-315.2% YoY 10-Q filed Aug 3, 2026
Diluted EPS
$-1.78
Q2 2026
+72.2% YoY 10-Q filed Aug 3, 2026
Operating cash flow
$-46.3M
YTD through Jun 30, 2026
-30.3% YoY 10-Q filed Aug 3, 2026
Free cash flow
$-46.3M
YTD through Jun 30, 2026
-29.2% YoY 10-Q filed Aug 3, 2026
Cash & equivalents
$64.2M
As of Jun 30, 2026
10-Q filed Aug 3, 2026
Assets
$441.7M
As of Jun 30, 2026
10-Q filed Aug 3, 2026
Liabilities
$19.1M
As of Jun 30, 2026
10-Q filed Aug 3, 2026
Stockholders’ equity
$422.6M
As of Jun 30, 2026
+952.9% YoY 10-Q filed Aug 3, 2026
Shares outstanding
53.5M
As of Jul 27, 2026
10-Q filed Aug 3, 2026
Current market context
Price performance
Dated price context from the historical market series already collected for this security.
Recent stored close
$22.96
View live quote ↗
52-week low
$14.85
May 7, 2026
52-week high
$28.38
Aug 27, 2026
Below 52-week high
19.1%
1W return
-4.6%
1M return
-5.2%
3M return
+31.7%
6M return
YTD return
1Y return
30-day volatility
72.9%
90-day volatility
72.6%
1Y max drawdown
-23.1%
Returns are close-to-close price changes. Volatility and drawdown are factual historical context, not recommendations.
How to read Schedule 13 ownership changes
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
For more context, see how to read a Schedule 13G, filing date vs event date, or Schedule 13G vs Schedule 13D.
Current ownership filings and reported ownership changes are available on free access. Investor and Pro add filing-specific significance scoring, disclosure-speed analysis, confirmation/divergence signals, and alerts. The overall institutional consensus preview remains public. Compare plans.
Beneficial ownership filing history
Showing 2 of 2 filing(s)View beneficial ownership filing evidence
| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| Goldman Sachs Group CIK0000886982 | Jun 30, 2026 quarter end Aug 14, 2026 filed Form 13F quarter-end evidence | Earlier Form 13F quarter-end holding Quarter-end holding evidence; no ownership percentage or signal. | 2.2M | $18.15 | |||
| Goldman Sachs Group CIK0000886982 | May 6, 2026 observed May 11, 2026 filed · 5d Initial Schedule 13G | Initial Schedule 13G | 2.8M | 5.50% | $16.00 | $15.25 | $18.15 |
Explore more institutional activity
Related research
Compare SPTX with other securities showing similar institutional activity or recent accumulation across several tracked institutions.